Drug Effects

Chemical Structure

Chemical Formula


Iupac Name

  • 1,
    1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purine-7-acetic acid with trans-4-[[(2-Amino-3,5-dibromophenyl)methyl]amino]cyclohexanol


  • Treatment and prevention of COPD (chronic pulmonary obstructive disease), chronic or acute asthma like bronchitis.

Adverse Effect

  • Stomach discomfort
  • Vomiting
  • Diarrhea
  • Constipation
  • Drowsiness
  • Heart burn
  • Itchiness
  • Urticaria
  • Leukocytosis and nasal inflammation
  • Bleeding in the esophageal
  • Changes in appetite

Mechanism Action

  • It indirectly clears up the excess build up of mucus in the airways. Also indirectly reduces airway inflammation.


  • AB Phylline (Acebrophylline) should only be used as instructed and prescribed by your physician or pharmacist. Do not alter your dosage unless specifically instructed to do so by either of the above. Dosage and usage often depends on the severity of the condition, as well as the patient's medical history and current health condition.
  • Before you begin using this medication, ensure your physician is aware of the following:
  • If you are pregnant or breastfeeding.
  • If you have any allergies.
  • If you have any other illnesses, disorders, or medical conditions.
  • If you are using any other drugs or medication.
  • If you are using any vitamins or supplements.

Drug Interaction

  • The plasma concentration of acebrophylline may be concurrent administration of erythromycin, cephalexin, oxytetracyclline, oligomycin, lincomycin, cimetidine, clindamycin, allopurinol, quinolones, anticoagulants, etc. If concurrent use is essential, the dose of acebrophylline should be reduced. 
  • The concomitant use of acebrophylline and frusimide can potentiate dieresis, while concomitant use of acebrophylline with reserpine can cause tachycardia. Acebrophylline plasma concentration may be decreased in patients by co administration with drugs like phenytoin and barbiturates and in patients with smoking habit. Not to use with CNS stimulants.


  • 100% Bioavailability.


  • 40%, primarily to albumin.


Hepatic to 1-methyluric acid


  • Renal.


1.  Daly JW, Jacobson KA, Ukena D. (1987). "Adenosine receptors: development of selective agonists and antagonists". Prog Clin Biol Res. 230 (1): 41–632.

2. Perouansky, M; Shamir M, Hershkowitz E, Donchin Y (12). 

3.  Essayan DM. (2001). "Cyclic nucleotide phosphodiesterases.". J Allergy Clin Immunol. 108 (5): 671–80.